Pfizer Embraces Biotech-Like Speed To Advance BCMA Bispecific

Phase II Pivotal Trial Under Way For Elranatamab In Multiple Myeloma

 
• By Mandy Jackson

Chris Boshoff, Pfizer Oncology chief development officer, said lessons from the rapid pace of the company’s COVID-19 vaccine program are being applied to elranatamab and other cancer therapies.

3D Rendering of abstract highway path through digital binary towers in city
Pfizer is advancing its oncology pipeline with biotech-like speed and pharma scale • Source: Shutterstock

More from Strategy

More from Business